Rite Aid (RAD) Tops Q4 EPS by 6c; Issues Strong FY15 Outlook

Rite Aid (NYSE: RAD) reported Q4 EPS of $0.10, $0.06 better than the analyst estimate of $0.04. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.54 billion.

Same store sales for the quarter increased 2.1 percent over the prior year, consisting of a 3.5 percent increase in pharmacy sales, partially offset by a 0.7 percent decrease in front end sales. Pharmacy sales included an approximate 123 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores decreased 1.8 percent over the prior year period, with 1.3 percent of this decrease being driven by a decrease in flu-related prescriptions and flu shots. Prescription sales accounted for 67.5 percent of total drugstore sales, and third party prescription revenue was 97.1 percent of pharmacy sales.

Sees FY2015 EPS of $0.31 - $0.42, versus the consensus of $0.35. The company also sees FY2015 revenue of $26.0 - $26.5 billion, versus the consensus of $25.75 billion. Same store sales are expected to range from an increase of 2.50 percent to an increase of 4.50 percent over fiscal 2014. Adjusted EBITDA (which is reconciled to net income on the attached table) is expected to be between $1.325 billion and $1.4 billion.

For earnings history and earnings-related data on Rite Aid (RAD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c